Collegium Pharmaceutical, Inc. (COLL) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $21.85 (-4.21%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 10, 2026 | Les Sulewski | Truist Financial | $58.00 | +165.4% |
| Feb 4, 2025 | David Amsellem | Piper Sandler | $36.00 | +64.8% |
| Nov 11, 2024 | Glen Santangelo | Jefferies | $40.00 | +83.1% |
| Sep 4, 2024 | Oren Livnat | H.C. Wainwright | $50.00 | +128.8% |
| Aug 9, 2024 | David Amsellem | Piper Sandler | $37.00 | +69.3% |
| Jul 30, 2024 | Oren Livnat | H.C. Wainwright | $47.00 | +115.1% |
| Jun 7, 2024 | Glen Santangelo | Jefferies | $44.00 | +101.4% |
| May 10, 2024 | David Amsellem | Piper Sandler | $39.00 | +78.5% |
Top Analysts Covering COLL
COLL vs Sector & Market
| Metric | COLL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.17 | 2.25 | 2.42 |
| Analyst Count | 6 | 8 | 18 |
| Target Upside | +107.0% | +16187.1% | +19.5% |
| P/E Ratio | 10.71 | 3.78 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $204M | $207M | $208M | 1 |
| 2026-12-31 | $215M | $217M | $218M | 2 |
| 2027-03-31 | $146M | $147M | $148M | 1 |
| 2027-06-30 | $153M | $155M | $156M | 2 |
| 2027-09-30 | $156M | $158M | $159M | 2 |
| 2027-12-31 | $161M | $163M | $164M | 1 |
| 2028-12-31 | $615M | $663M | $719M | 3 |
| 2029-12-31 | $688M | $742M | $804M | 2 |
| 2030-12-31 | $712M | $768M | $833M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.89 | $1.92 | $1.93 | 1 |
| 2026-12-31 | $1.99 | $2.02 | $2.04 | 1 |
| 2027-03-31 | $1.38 | $1.40 | $1.41 | 1 |
| 2027-06-30 | $1.53 | $1.55 | $1.56 | 1 |
| 2027-09-30 | $1.71 | $1.73 | $1.74 | 1 |
| 2027-12-31 | $1.78 | $1.81 | $1.82 | 1 |
| 2028-12-31 | $5.28 | $5.83 | $6.47 | 1 |
| 2029-12-31 | $8.04 | $8.88 | $9.85 | 1 |
| 2030-12-31 | $8.49 | $9.38 | $10.41 | 1 |
Frequently Asked Questions
What is the analyst consensus for COLL?
The consensus among 6 analysts covering Collegium Pharmaceutical, Inc. (COLL) is Buy with an average price target of $58.00.
What is the highest price target for COLL?
The highest price target for COLL is $58.00, set by Les Sulewski at Truist Financial on 2026-02-10.
What is the lowest price target for COLL?
The lowest price target for COLL is $36.00, set by David Amsellem at Piper Sandler on 2025-02-04.
How many analysts cover COLL?
6 analysts have issued ratings for Collegium Pharmaceutical, Inc. in the past 12 months.
Is COLL a buy or sell right now?
Based on 6 analyst ratings, COLL has a consensus rating of Buy (2.17/5) with a +107.0% upside to the consensus target of $58.00.
What are the earnings estimates for COLL?
Analysts estimate COLL will report EPS of $1.92 for the period ending 2026-09-30, with revenue estimated at $207M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.